


Schema



*For Canadian sites only: Pembrolizumab 2 mg/kg (maximum dose to 200 mg) IV is alternative dosing permitted at CCTG sites.

Treatment or observation is to continue for 27 weeks or until unacceptable adverse event. Patients will be followed for 5 years after registration or recurrence. Thereafter, patients will be followed annually (+/- 3 months) for overall survival for a total of 10 years after registration.

Please refer to the full protocol text for a complete description of the eligibility criteria and treatment plan.

If the Group credited for enrollment is a non-Alliance Group, then other requirements from the credited Group may apply.

Until institutions receive a formal notice from the Alliance regarding termination to patient follow-up, institutions must not close this trial with the IRB of record for the study. Please contact the Alliance Regulatory team at regulatory@alliancenctn.org with any questions.